Prioritizing vaccine boosters for vulnerable patients could prevent emergence of new COVID variants
Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine ...
BofA maintains Buy on AstraZeneca stock, GBP145.00 target
BofA Securities reiterated its Buy rating on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), with a steady price target of GBP145.00. The firm's positive stance is based on the pharmaceutical giant's ...
AstraZeneca initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...
Morgan Stanley sets AstraZeneca stock Overweight with £145 target
AstraZeneca PLC (LON:AZN:LN) (NASDAQ: AZN), a pharmaceutical giant with a market capitalization of $224.5 billion, received a new Overweight rating from Morgan Stanley (NYSE:MS), accompanied by a ...
AstraZeneca (AZN) Gets a Buy from Bernstein
In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
A leading pediatrician was already worried about the future of vaccines. Then RFK Jr. came along
In a new book, pediatric infectious disease specialist Dr. Adam Ratner details the history of measles, a virus that’s often a ...
AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China
Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...
Why AstraZeneca Topped the Market on Thursday
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...